クロナゼパム
クロナゼパムは強力で長時間作用型の**ベンゾジアゼピン系**薬物であり、獣医療では主に補助的な抗てんかん薬および抗不安薬として使用されます。 > **臨床上のポイント:** 犬では、抗てんかん効果に対する耐性が急速に(通常1〜4週間以内に)発現するため、長期的な維持抗てんかん薬としての有用性は非常に限られています。これは受容体のダウンレギュレーションと薬物動態の変化によるものです。したがって、短期間のパルス療法や群発発作の管理にはるかに適しています。 - 猫では、てんかんや不安の長期的な補助治療に使用できます。猫における経口ベンゾジアゼピン系薬物(特にジアゼパム)は特異体質性の急性肝壊死を引き起こすリスクが知られていますが、クロナゼパムではその可能性は低いと考えられています。ただし、モニタリングは依然として必要です。 - クロナゼパムは、ヒトにおける乱用および依存の可能性があるため、**スケジュールIV(C-IV)**の規制薬物に指定されています。
作用機序: Clonazepam acts as a positive allosteric modulator at the **GABA-A receptor** complex in the central nervous system. - It binds to specific benzodiazepine receptors (located primarily in the limbic, thalamic, and hypothalamic regions) → enhances the affinity of the receptor for the inhibitory neurotransmitter **gamma-aminobutyric acid (GABA)**. - This increases the frequency of chloride channel opening → influx of chloride ions → cellular hyperpolarization → decreased neuronal excitability. - Additional postulated mechanisms include antagonism of serotonin and diminished release or turnover of acetylcholine in the CNS.
動物種別の用量
- Anxiolytic · 0.05-0.25 mg/kg PO q12-24h · PO · q12-24h
- Anxiolytic · 0.02-0.2 mg/kg PO once to two times a day · PO · q12-24h
- Anxiolytic · 0.1-0.2 mg/kg PO as needed or up to two times a day · PO · PRN or q12h
- Adjunctive medication in the treatment of seizures · Starting dose is 0.5 mg (total dose) PO q12-24h · PO · q12-24h
- Adjunctive medication in the treatment of seizures · 1/8th to 1/4 of a 0.5 mg tablet PO two to three times daily · PO · q8-12h · Anecdotally more effective for maintenance and to decrease cluster seizures; acute hepatic necrosis possible
- Anxiolytic / Hyperaesthesia / Epilepsy · 0.5 mg/cat · PO · q12-24h · Suggested starting dose but there is a wide range of recommendations.
- Adjunctive medication in the treatment of seizures · 1-2 mg/kg PO q12h · PO · q12h
- Adjunctive medication in the treatment of seizures · 0.5 mg/kg PO two to three times a day · PO · q8-12h · May need to lower phenobarbital dose by 10-20%
- Anxiolytic · 0.05-0.25 mg/kg PO q12-24h · PO · q12-24h
- Anxiolytic · 0.1-1 mg/kg PO two to three times a day · PO · q8-12h
投与経路
禁忌
- Hypersensitivity to clonazepam or other benzodiazepines
- Significant liver disease or dysfunction
- Acute narrow-angle glaucoma
- Myasthenia gravis (may exacerbate weakness)
- Marked CNS depression
- Respiratory depression
- Severe muscle weakness
- Hepatic impairment (may worsen hepatic encephalopathy)
- Acute narrow angle glaucoma
有害事象
- Sedation and lethargy
- Ataxia (incoordination)
- Paradoxical excitement, hyperactivity, or vocalization
- Increased salivation
- Gastrointestinal upset (vomiting, diarrhea, constipation)
- Dogs: Rapid tolerance to anticonvulsant effects
- Cats: Polyphagia, potential for acute hepatic necrosis (rare)
- Sedation
- Respiratory suppression (at higher doses)
- Ataxia
- Acute hepatic necrosis (idiosyncratic in cats)
- Tolerance development
薬物相互作用
- Azole Antifungals (itraconazole, ketoconazole) · May increase clonazepam levels by inhibiting its metabolism.
- Cimetidine · May decrease the metabolism of benzodiazepines, increasing their effects.
- CNS Depressants (barbiturates, narcotics, anesthetics) · Additive CNS depression; may cause profound sedation or respiratory depression.
- Erythromycin · May decrease the metabolism of benzodiazepines.
- Phenobarbital · May decrease clonazepam concentrations via hepatic enzyme induction. · moderate
- Phenytoin · May decrease clonazepam concentrations. · moderate
- Propantheline · May decrease clonazepam concentrations.
- Rifampin · May induce hepatic microsomal enzymes and decrease the pharmacologic effects of benzodiazepines.
- Antifungal imidazoles (e.g., Ketoconazole, Itraconazole) · Inhibition of CYP450 enzymes may decrease clonazepam clearance, increasing its plasma levels and risk of toxicity. · moderate
- Other CNS Depressants · Additive sedation and respiratory depression. · major
モニタリング
- Clinical efficacy (seizure frequency, anxiety levels)
- Adverse effects (sedation, ataxia, paradoxical excitement)
- Therapeutic blood levels (reported target: 0.015-0.07 mcg/mL)
- Cats: Baseline and periodic liver function tests
- Degree of sedation and ataxia
- Respiratory rate and effort
- Hepatic function panel (especially in cats)
- Clinical response (seizure frequency, muscle tone, or behavioral changes)
過量投与
Overdoses commonly cause profound **sedation, depression, and ataxia**. - **Paradoxical Reactions:** Some animals may exhibit paradoxical signs such as hyperactivity, disorientation, agitation, and vocalization. Paradoxical excitation can be treated with a mild sedative, such as diphenhydramine. - **Management:** Emesis is generally NOT indicated due to the risk of rapid CNS depression and aspiration. Mild to moderate overdoses can often be monitored at home if the animal is rousable and not showing paradoxical signs. Keep the animal confined and minimize stimulation. - **Severe Toxicity:** Massive overdoses can lead to respiratory depression or hypotension. **Flumazenil** (a specific benzodiazepine antagonist) can be used to reverse severe respiratory or CNS depression. Because flumazenil has a short half-life, multiple doses may be required.
VetSheet の薬剤リファレンスは、獣医療従事者向けの臨床意思決定支援を目的としており、専門的判断やメーカーの最新添付文書に代わるものではありません。